USPTO serial 98473700
MULTIPLYING THE POSSIBILITIES
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- SALTZMAN, DANIEL R
- Law office
- TMO LAW OFFICE 111
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with MULTIPLYING THE POSSIBILITIES?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Joi A. White
Joi A. White Carr & Ferrell LLP411 Borel Avenue, Suite 603San Mateo, CA 94402United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceuticals for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; pharmaceutical preparations for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; pharmaceutical substances for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; therapeutics for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; therapeutic agents for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; gene therapy systems used to express therapeutic proteins in vivo for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; biopharmaceuticals for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; medicines for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; drugs for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; vaccines; in vivo cell therapies for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; cells for medical or clinical use; stem cells for medical purposes; cells for medical use; genetically engineered cells for medical purposes; gene therapy products, namely, lipid nanoparticle encapsulated nucleic acids; gene therapy preparations, in the nature of lipid nanoparticle encapsulated nucleic acids; gene therapy pharmaceutical preparations for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; gene therapy products, namely, genetically engineered cells for transplant purposes; targeted in vivo RNA technologies for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; targeted lipid nanoparticles for medicinal use; targeted lipid nanoparticles for durable cell reprogramming or cell engineering; targeted lipid nanoparticles for transient cell reprogramming or cell engineering; cell engineering platforms for treatment of human diseases, disorders and conditions; cell platforms for treatment of human diseases, disorders and conditions; technology platforms for developing and engineering therapeutic cells for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; in vivo cell engineering platforms for developing and engineering therapeutic cells, transient gene therapy, and durable gene therapy for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; transient in vivo cell engineering platforms for durable gene therapy for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 20, 2025 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Nov 20, 2025 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jul 29, 2025 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Jul 29, 2025 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| May 7, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 7, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 7, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 8, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 8, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 8, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 8, 2025 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Jan 8, 2025 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Oct 10, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 10, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 10, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 9, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 2, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 28, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 28, 2024 | NWAP | NEW APPLICATION ENTERED | — |